Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kinetic resistance to anticancer agents

M T Dimanche-Boitrel1, C Garrido, B Chauffert

  • 1INSERM 252, Faculty of Medicine, Dijon, France.

Cytotechnology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidisciplinary management of X-linked myotubular myopathy in Spain and Portugal: A case series analysis.

Neurologia·2026
Same author

Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.

Oncogene·2025
Same author

Editorial Expression of Concern: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.

Oncogene·2025
Same author

Microscopic fractional anisotropy outperforms multiple sclerosis lesion assessment and clinical outcome associations over standard fractional anisotropy tensor.

Human brain mapping·2024
Same author

A pivotal role for the IL-1β and the inflammasome in preterm labor.

Scientific reports·2024
Same author

Synthetic MRI in subarachnoid haemorrhage.

Clinical radiology·2021
Same journal

Combination of paclitaxel with eugenol effectively enhances anticancer characteristics of paclitaxel on the A549 lung cancer cell line.

Cytotechnology·2026
Same journal

RBM15 enhances ILDR1 n6-methyladenosine methylation to accelerate gastric adenocarcinoma progression via an IGF2BP3-dependent manner.

Cytotechnology·2026
Same journal

Apigenin attenuates hepatocyte senescence in metabolic dysfunction-associated steatotic liver disease by targeting the TGF-β signaling pathway.

Cytotechnology·2026
Same journal

Iodine-125 seed induces ferroptosis through inhibiting RNF216-mediated ubiquitination of p53 in cholangiocarcinoma cells.

Cytotechnology·2026
Same journal

Magnetic resonance imaging-based Alzheimer's disease detection using an EfficientNet-CMSACCN framework.

Cytotechnology·2026
Same journal

Brusatol Induces Ferroptosis in Condyloma Acuminatum Keratinocytes by Suppressing Nrf2 via Inhibition of the PI3K/AKT Pathway.

Cytotechnology·2026
See all related articles

Confluent cancer cells show resistance to chemotherapy due to reduced drug uptake and DNA repair. Strategies to overcome this resistance involve stimulating cell proliferation or recruiting quiescent cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Adherent epithelial cancer cells, like colon cancer cells, exhibit increased resistance to anticancer agents at confluence.
  • This confluence-dependent resistance (CDR) is a significant factor in the natural resistance of solid tumors to chemotherapy.

Purpose of the Study:

  • To investigate the mechanisms underlying confluence-dependent resistance (CDR) in cancer cells.
  • To understand why certain chemotherapy drugs are less effective in confluent cell populations.

Main Methods:

  • Comparative analysis of drug accumulation in confluent versus nonconfluent cancer cells.
  • Investigation of membrane fluidity and its role in drug transport.
  • Assessment of topoisomerase II levels and DNA damage in relation to cell proliferation state.

Related Experiment Videos

Main Results:

  • Certain drugs (anthracyclines, etoposide, vincristine) accumulate less in confluent cells, linked to reduced membrane fluidity.
  • The primary mechanism of CDR involves increased intrinsic DNA resistance, particularly for drugs targeting topoisomerase II.
  • Confluent cells have lower topoisomerase II levels, resulting in fewer drug-induced DNA strand breaks compared to nonconfluent cells.

Conclusions:

  • Confluence-dependent resistance in cancer cells is mediated by decreased drug transport and, predominantly, by reduced DNA damage susceptibility.
  • Lower topoisomerase II expression in quiescent confluent cells contributes to resistance against specific chemotherapeutics.
  • Potential strategies to overcome CDR include stimulating cell proliferation or synchronizing cell cycles using specific agents.